TNXPTonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, an…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline Tonix Pharmaceuticals (NASDAQ:TNXP) is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing development programs in Lyme disease prevention and major depressive disorder, Chief Executive Officer Seth Lederman said during a Canaccord Genuity conference p | ||
 Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript TONMYA sales hit $11 million in its second quarter on market. | ||
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ... Tonix Pharmaceuticals reports record TONMYA sales of $11 million in Q2 2026, with prescriptions doubling quarter-over-quarter and market access expanding to 136 million covered lives. | ||
 Tonix Pharmaceuticals Q2 Earnings Call Highlights Tonix Pharmaceuticals (NASDAQ:TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said Tonmya sales rose 197% from the first quarter, its second full quarter of commercial sales following the | ||
 Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP) Medicare Deal Broadens Access to TONMYATonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has signed a new managed Medicare payer agreement for its fibromyalgia treatment TONMYA® (cyclobenzaprine HCl sublingual tablets), extending the drug’s potential coverage to around 9 million additional Medicare beneficiaries. | ||
TThe Fly | ||